Immatics Overview

  • Founded
  • 2000
Founded
  • Status
  • Public
  • Employees
  • 198
Employees
  • Stock Symbol
  • IMTX
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $10.83
  • (As of Tuesday Closing)

Immatics General Information

Description

Immatics NV is engaged in the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • Paul-Ehrlich-Street 15
  • 72076 Tübingen
  • Germany
+49 07071 00000

Immatics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Immatics Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$10.83 $11.00 $8.66 - $18.42 $692M 62.9M 809K -$5.44

Immatics Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 382,371 382,371
Revenue 35,626 35,626 20,653 4,449
EBITDA (257,339) (257,339) (32,743) (36,193)
Net Income (261,107) (261,107) (35,342) (37,106)
Total Assets 313,206 313,206 150,413
Total Debt 7,610 7,610 3,623 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Immatics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Immatics‘s full profile, request access.

Request a free trial

Immatics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Immatics NV is engaged in the discovery of true targets for cancer immunotherapies with the development of the right T c
Biotechnology
Tübingen, Germany
198 As of 2020
00000
000000000 00000

0000 000

xercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repreh
000000000000000
Cambridge, MA
000 As of 0000
00000
00000000 00000

0000000

nim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis
0000 000000000
San Diego, CA
000 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Immatics Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
TCR2 Therapeutics Formerly VC-backed Cambridge, MA 000 00000 00000000 00000
0000000 0000000000 Formerly VC-backed San Diego, CA 000 00000 00000000 00000
000000 Venture Capital-Backed Utrecht, Netherlands 00 00.000 000000000000 00.000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000 000000000000 Formerly VC-backed Houston, TX 00 00000 000000&0 00000
You’re viewing 5 of 13 competitors. Get the full list »

Immatics Executive Team (20)

Name Title Board Seat Contact Info
Harpreet Singh Ph.D Chief Executive Officer & Founder
Thomas Ulmer Chief Financial Officer, Finance
Steffen Walter Ph.D Chief Technology Officer, Technology
Rainer Kramer Ph.D Managing Director & Chief Business Officer
Silvio Rometsch Director, Information Technology
You’re viewing 5 of 20 executive team members. Get the full list »

Immatics Board Members (13)

Name Representing Role Since
Adam Stone Self Board Member 000 0000
Christof Hettich Self Board Member 000 0000
Erich Schlick Wellington Partners Board Member 000 0000
Friedrich Von Bohlen Ph.D dievini Board Member 000 0000
Harald Stock Ph.D Self Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Immatics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immatics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Immatics‘s full profile, request access.

Request a free trial

Immatics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 00000000 0000 01-Jul-2020 000000000000000000 Special Purpose Acquisition Company (SPAC) 00000000 00000 00.0
To view Immatics’s complete acquisitions history, request access »